TRYG Foundation   Report issue

Foundation Phase 3 Phase 4
Founded: Copenhagen Denmark (1998)

Organization Overview

First Clinical Trial
2009
NCT00975962
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

TrygFonden, Denmark | TRYG Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypersensitivity (Phase 3)

Mental Disorders (Phase 4)

Psychotic Disorders (Phase 4)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 10